Company intelligence / Profile preview
Merakris Therapeutics
Research Triangle Park, North Carolina, United Statesmerakris.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Currently conducting Phase 2 clinical trials for MTX-001 (Dermacyte Liquid), a subcutaneous injectable for venous leg ulcer healing. Interim data from Phase 2 trials has been published in the International Wound Journal with positive results. The company is targeting late-2025 for completion of the current Phase 2 study.
- Therapeutic areas
- OphthalmologyEndocrinologyCardiovascularDermatology
- Modalities
- Cell-free biologicsAmniotic fluid-derived therapeutics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
US Department of Veterans Affairs
Beyond the preview
Go deeper on Merakris Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merakris Therapeutics.